Odyssey Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-04.
Odyssey Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 4, 2025. The filing reports $214.03M sold. Its industry group is Biotechnology. It names Gary Glick (Executive Officer, Director), Carl Gordon (Director), Jill Carroll (Director) (SEC Form D, December 4, 2025).
Sell to companies like Odyssey Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Odyssey Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Odyssey Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in December 2025, largest first.
Get an email when Odyssey Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Odyssey Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Odyssey Therapeutics, Inc. →Get the full cited report on Odyssey Therapeutics, Inc.
What the filing shows about Odyssey Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Odyssey Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Odyssey Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $214.03M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Gary Glick is named as Executive Officer and Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Carl Gordon is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Jill Carroll is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Valerie Odegard is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Nan Li is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Jeffrey Leiden is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Paulina Hill is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Timothy Walbert is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
lan Smith is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Shelley Chu is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Ksenija Pavletic is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Carolyn Ng is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
Nia Tatsis is named as Director on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
On the filing as: Executive Officer.
Jason Haas is named as Cfo on the Form D that Odyssey Therapeutics, Inc. filed with the SEC on 4 December 2025, one of 14 people that filing names.
14 people named on the filing — 2 holding an executive role and 12 as directors only.
Named as of the 2025-12-04 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 14 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Odyssey Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Odyssey Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Odyssey Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Odyssey Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Odyssey Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Odyssey Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/odyssey-therapeutics-inc-form-d-25000001